No Fed urgency leaves stocks at risk: JPMorgan

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 44 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 53%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

No Fed urgency leaves stocks at risk: JPMorgan

JPMorgan analysts have raised concerns that the current equity market is increasingly a"two-sided debate," with risks stemming from potential growth downturns, uncertain Fed timing, and various geopolitical factors.

The bank explains that in the first half of the year, market attention was largely focused on the trajectory of inflation. However, the second half of the year is shifting attention to growth risks, particularly given the elevated earnings expectations for the latter half of 2024 and for 2025 . The current market pullback is seen as a reaction to fears of weakening growth and a reassessment of recession probabilities.

However, they conclude:"While the recent market flush took out some of the froth, equity positioning and valuation still remain at risk especially if growth continues to decelerate and the Fed does not show urgency."Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 450. in BE
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

JPMorgan stock price at record high ahead of Q2 earningsJPMorgan earnings kick off earnings season on 12 July, but a slowdown is expected despite the stock’s run to record highs.
La source: DailyFX - 🏆 305. / 63 Lire la suite »

Here are JPMorgan's top drug stock picks into earningsThese are JPMorgan's top drug picks heading into earnings.
La source: CNBC - 🏆 12. / 72 Lire la suite »